Landec Corp \Ca\ LNDC
We take great care to ensure that the data presented and summarized in this overview for LANDEC CORP \CA\ is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LNDC
View all-
Wynnefield Capital Inc New York, NY4.7MShares$00.0% of portfolio
-
Legion Partners Asset Management, LLC Los Angeles, CA4.43MShares$00.0% of portfolio
-
Greenhaven Road Investment Management, L.P. Greenwich, CT3.62MShares$00.0% of portfolio
-
325 Capital LLC New York, NY2.16MShares$00.0% of portfolio
-
22 Nw, LP Seattle, WA1.76MShares$00.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.53MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY1.45MShares$00.0% of portfolio
-
Morgan Stanley New York, NY745KShares$00.0% of portfolio
-
Geode Capital Management, LLC Boston, MA686KShares$00.0% of portfolio
-
Invesco Ltd. Atlanta, GA556KShares$00.0% of portfolio
Latest Institutional Activity in LNDC
Top Purchases
Top Sells
About LNDC
Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, and filled products. In addition, it offers O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products. The company operates in the United States, Canada, and internationally. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.
Insider Transactions at LNDC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2025
|
Paul Josephs Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
17,000
+2.95%
|
$85,000
$5.74 P/Share
|
|
Dec 06
2024
|
Ryan David Lake Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,653
-1.75%
|
$39,571
$7.15 P/Share
|
|
Dec 06
2024
|
Ryan David Lake Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,720
+5.75%
|
-
|
|
Dec 06
2024
|
Paul Josephs Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,769
-2.12%
|
$82,383
$7.15 P/Share
|
|
Dec 06
2024
|
Paul Josephs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,461
+6.49%
|
-
|
|
Oct 07
2024
|
Ryan David Lake Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,138
-10.12%
|
$170,690
$5.09 P/Share
|
|
Oct 07
2024
|
Ryan David Lake Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+18.18%
|
-
|
|
Oct 03
2024
|
Wynnefield Partners Small Cap Value LP I > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
169,753
+6.11%
|
$679,012
$4.1 P/Share
|
|
Oct 03
2024
|
Wynnefield Partners Small Cap Value LP I > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
122,930
+5.54%
|
$491,720
$4.1 P/Share
|
|
Oct 03
2024
|
Christopher S Kiper Director |
BUY
Open market or private purchase
|
Indirect |
1,463,414
+28.29%
|
$5,853,656
$4.1 P/Share
|
|
Sep 03
2024
|
Ryan David Lake Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
262,500
+50.0%
|
-
|
|
Aug 19
2024
|
Paul Harold Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,554
+50.0%
|
-
|
|
Aug 19
2024
|
Humberto Calheiros Antunes Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,554
+50.0%
|
-
|
|
Aug 19
2024
|
Matthew E Korenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,554
+50.0%
|
-
|
|
Aug 19
2024
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,554
+50.0%
|
-
|
|
Jul 08
2024
|
Nathaniel Calloway Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+34.06%
|
-
|
|
Jul 08
2024
|
Craig A. Barbarosh Director |
BUY
Grant, award, or other acquisition
|
Indirect |
30,000
+25.41%
|
-
|
|
Jul 08
2024
|
Jeffrey L Edwards Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.36%
|
-
|
|
Jul 08
2024
|
Raymond H Diradoorian Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+30.01%
|
-
|
|
Jul 08
2024
|
Joshua Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.5%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.18M shares |
|---|---|
| Exercise of conversion of derivative security | 75K shares |
| Open market or private purchase | 1.77M shares |
| Payment of exercise price or tax liability | 60.5K shares |
|---|